drugset / Trial / NCT06393673
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
RandomizedParallel-groupDouble-blindTreatment
Summary
A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.
Timeline
- Start
- 2024-05-30
- Primary completion
- 2025-06-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10384 | Unknown | — | Oral |
Indications
No indication recorded.